Bavarian Nordic (OTCPK:BVNR.Y) - Prezzo delle azioni, notizie e analisi

BVNR.Y Panoramica delle azioni

Bavarian Nordic A/S sviluppa, produce e commercializza vaccini salvavita. Maggiori dettagli

BVNR.Y analisi fondamentale
Punteggio fiocco di neve
Valutazione	5/6
Crescita futura	0/6
Prestazioni passate	5/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Negoziato a 62% al di sotto della nostra stima del suo valore equo

Gli utili sono cresciuti del 54.6% nell'ultimo anno

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 3.6% all'anno per i prossimi 3 anni

Bavarian Nordic A/S Concorrenti

MannKind

NasdaqGM:MNKD

US$1.9b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

ADMA Biologics

NasdaqGM:ADMA

US$4.5b

Agios Pharmaceuticals

NasdaqGS:AGIO

US$3.1b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Bavarian Nordic
Prezzi storici delle azioni
Prezzo attuale dell'azione	DKK 8.72
Massimo di 52 settimane	DKK 14.60
Minimo di 52 settimane	DKK 6.86
Beta	1.58
1Variazione di 1 mese	-17.23%
Variazione a 3 mesi	-31.01%
Variazione di 1 anno	16.34%
3Variazione a 3 anni	-43.01%
Variazione a 5 anni	6.73%
Variazione dall'IPO	47.63%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	BVNR.Y	US Biotechs	US Mercato
7D	-11.0%	-10.3%	-2.1%
1Y	16.3%	13.6%	29.6%

Ritorno vs Industria: BVNR.Y ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 13.6 % nell'ultimo anno.

Rendimento vs Mercato: BVNR.Y ha avuto una performance inferiore al mercato US che ha registrato un rendimento 29.6 % nell'ultimo anno.

Volatilità dei prezzi

Is BVNR.Y's price volatile compared to industry and market?
BVNR.Y volatility
BVNR.Y Average Weekly Movement	6.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: BVNR.Y non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 7% ) di BVNR.Y è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1992	1,609	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S sviluppa, produce e commercializza vaccini salvavita. L'azienda offre vaccini non replicanti contro il vaiolo e il vaiolo delle scimmie con i nomi IMVAMUNE, IMVANEX e JYNNEOS; vaccino antirabbico per uso umano con il nome Rabipur/RabAvert; vaccino contro l'encefalite da zecche con il nome Encepur; e vaccino contro l'ebola con il nome MVABEA. L'azienda sta inoltre sviluppando MVA-BN per il trattamento del vaiolo; MVA-BN RSV, che è in fase III di sperimentazione clinica per il trattamento del virus respiratorio sinciziale; ABNCoV2 che ha completato la Fase III di sperimentazione clinica per il trattamento della SARS-CoV-2.

Bavarian Nordic A/S Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Bavarian Nordic con la sua capitalizzazione di mercato?
BVNR.Y statistiche fondamentali
Capitalizzazione di mercato	US$2.05b
Guadagni(TTM)	US$157.86m
Ricavi(TTM)	US$856.60m

13.0x

Rapporto P/E

2.4x

Rapporto P/S

BVNR.Y è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
BVNR.Y Conto economico (TTM)
Ricavi	DKK 6.07b
Costo del fatturato	DKK 2.33b
Profitto lordo	DKK 3.74b
Altre spese	DKK 2.62b
Guadagni	DKK 1.12b

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

Mar 05, 2025

Utile per azione (EPS)	14.24
Margine lordo	61.57%
Margine di profitto netto	18.43%
Rapporto debito/patrimonio netto	0.1%

Come si è comportato BVNR.Y nel lungo periodo?

Vedi performance storica e confronto

BVNR.Y Panoramica delle azioni

Premi

Analisi del rischio

Bavarian Nordic A/S Concorrenti

NasdaqGM:MNKD

US$1.9b

NasdaqCM:CPRX

US$2.5b

NasdaqGM:ADMA

US$4.5b

NasdaqGS:AGIO

US$3.1b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Recent updates

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021

Bavarian Nordic A/S has completed a Follow-on Equity Offering in the amount of DKK 1.14845 billion.

Bavarian Nordic A/S Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial